Lp(a)对选择性与计量学缺陷的容忍度远低于多数生物标志物
脂蛋白(a)是ASCVD的因果风险因素,但因其载脂蛋白(a)异构体大小异质性和遗传变异共存,免疫分析校准与跨方法可比性面临挑战,可能导致心血管风险误分类。Lp(a)检测的标准化历经数十年,现认识到除校准问题外还存在被测量异质性问题,因此Lp(a)的协调最终需要明确定义被测量,并支持从质量标准化向摩尔标准化过渡。
要点
- Lp(a)是ASCVD的因果风险因素,但检测标准化仍具挑战性。
- 载脂蛋白(a)异构体异质性和遗传变异影响免疫分析校准与跨方法可比性。
- Lp(a)协调需明确定义被测量,并支持从质量标准化向摩尔标准化过渡。
核心结论
- Lp(a)的标准化挑战不仅源于校准问题,还存在被测量异质性问题,需明确定义被测量并推动摩尔标准化。
主要发现
- 载脂蛋白(a)异构体大小异质性和遗传变异共存影响免疫分析校准与跨方法可比性,可能导致心血管风险误分类并影响临床决策。
- 不同选择性的Lp(a)检测方法揭示了被测量异质性问题。
临床怎么用
- 临床解读Lp(a)结果时应考虑检测方法的选择性差异及被测量异质性对风险分类的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite being an established causal risk factor for ASCVD, lipoprotein(a) (Lp(a)) remains one of the most misunderstood metrics in cardiovascular risk assessment and clinical practice. Standardization of Lp(a) measurement remains challenging due to the marked heterogeneity in apolipoprotein(a) isoform size and co-existence of genetic variants, which affect immunoassay calibration and inter-method comparability, potentially leading to misclassification of cardiovascular risk and impacting clinical decision-making. Stakeholders concerned about accuracy of Lp(a) testing have spent decades trying to solve what was considered a calibration problem for Lp(a). We currently know there is also a measurand heterogeneity problem as revealed by Lp(a) assays with different selectivity's. Consequently, Lp(a) harmonization ultimately requires a clearly defined measurand and supports the transition from mass-based to molar standardization.
引用
- Cobbaert C. Unlike most biomarkers, Lp(a) is far less forgiving on selectivity and metrological shortcomings. Clin Chem Lab Med. 2026. PMID: 42937532. doi:10.1515/cclm-2026-1787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。